TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01942863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procedural Requirements
Description: SBE was advanced as deeply as possible and complete small bowel visualization was attempted. When the following conditions were met, tattooing at the deepest position with India ink was performed and the endoscope was withdrawn: no further endoscopic advancement could be achieved, detection of a significant lesion and no other lesions suspected, severe stricture, obvious sedation and SBE-related adverse events happened which required termination of further intubation.
Study: NCT02851992

Intervention type: DEVICE
Group type: OTHER
Intervention: GTS cementless stem
Description: Total Hip Arthroplasty
Study: NCT01283256

Intervention type: DRUG
Intervention: zonisamide
Description: zonisamide 100mg tablets
Study: NCT01335971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulforaphane 25
Description: 25 micromoles (4.4 mg) sulforaphane daily by mouth

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sulforaphane 150
Description: 150 micromoles (26.6 mg) sulforaphane daily by mouth

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose once daily by mouth
Study: NCT01948362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulforadex
Description: Active compound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha cyclodextrin
Description: Placebo control
Study: NCT00772161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Comparison of two extended-release formulations of 20mg Methylphenidate in a cross-over design.
Study: NCT02357420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relamorelin
Description: Double blind relamorelin was given subcutaneously BID for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relamorelin
Description: Double blind relamorelin was given subcutaneously BID for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relamorelin
Description: Double blind relamorelin was given subcutaneously BID for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given subcutaneously for 12 weeks.
Study: NCT01991249

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood draw
Study: NCT02456337

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mucograft
Description: Coronally advanced flap associated to Xenogenous collagen matrix graft (mucograft) for the treatment of gingival recessions Miller Class I or II.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mucograft
Description: Coronally advanced flap associated to Xenogenous collagen matrix graft (mucograft) for the treatment of gingival recessions Miller Class I or II.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Emdogain
Description: Coronally advanced flap associated to Enamel Matrix Derivative (Emdogain) for the treatment of gingival recessions Miller Class I or II.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emdogain
Description: Coronally advanced flap associated to Enamel Matrix Derivative (Emdogain) for the treatment of gingival recessions Miller Class I or II.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronally Advanced flap
Description: Coronally advanced flap for the treatment of gingival recessions Miller Class I or II.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronally Advanced flap
Description: Coronally advanced flap for the treatment of gingival recessions Miller Class I or II.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronally Advanced flap
Description: Coronally advanced flap for the treatment of gingival recessions Miller Class I or II.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronally Advanced flap
Description: Coronally advanced flap for the treatment of gingival recessions Miller Class I or II.
Study: NCT02222896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate
Description: 2% CHG solution on cloth

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Excipients of CHG product only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DynaHex-2
Description: 2% CHG solution
Study: NCT00654329

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Normal saline, given intranasally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl, nasal transmucosal, 2 micrograms/kilogram
Study: NCT01935895

Intervention type: BEHAVIORAL
Intervention: Exercise on Blood Pressure Reactivity
Description: To comparison, volunteers randomly underwent 2 experimental sessions separated by 48-72h. The exercise session consisting of 3-laps in a circuit, performing resistance and aerobic exercises: knee extension, bench press, knee flexion, rowing in the prone, squat, shoulder press and five minutes of up to down in a 15cm high step between 75-85% heart rate maximum. Resistance exercise loads used dumbbells to upper body exercises and weights attached on the legs and arms to lower body exercises. Each resistance exercise was performed in 15reps with 50% of one repetition maximum test. Two secs for repetition were performed with rhythmic control. The control session was conducted under the same conditions of the exercise session, with the exception that subjects did not perform exercises.
Study: NCT01324830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: day 1 to day 5
Description: low to high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: day 1 to day 14
Description: low to high dose
Study: NCT03445702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 1000mg once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 1000mg once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic metformin 1000mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic metformin 1000mg
Study: NCT02292849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer to Peer
Description: 12 weekly sessions of peer-delivered behavioral activation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Mental Health Referral
Description: Standard mental health referral to a community agency
Study: NCT03760588

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sacubitril/valsartan
Description: Target dose 97/103 mg b.i.d .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Description: Target dose 97/103 mg b.i.d .
Study: NCT01941589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone
Description: maximal oral 5-ASA+/-topical 5-ASA+IV corticosteroids

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone
Description: maximal oral 5-ASA+/-topical 5-ASA+IV corticosteroids

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids only
Description: IV corticosteroids only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids only
Description: IV corticosteroids only
Study: NCT00654329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine, transmucosal, 1 microgram/kilogram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine, 2 microgram/kilogram, transmucosal route
Study: NCT03103932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarker guided discharge algorithm
Description: participants randomized to the biomarker guided discharge algorithm will follow a pre-determined care pathway for treatment of heart failure symptoms based on admission NTproBNP levels
Study: NCT02264496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT00974636

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Salt Diet
Description: Dietary sodium restriction of ≤2.0 g/day or ≤ 85 mmol/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Usual Salt Diet
Description: Usual salt intake (approximately \>180-200 mmol/day in the average American diet).
Study: NCT03237962

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula
Description: High Flow Nasal Cannula (HFNC) is an oxygen device that increases oxygenation and washes out CO2 within the dead space, it was also clinically used to correct hypoxemia, hypercapnia and respiratory failure.By providing flow rate that is similar to or higher than the patient's inspiratory flow, HFNC is able to provide ventilatory support. To produce stable oxygen concentration, HFNC entrains less air in order to reach the preset value.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Cannula
Description: Nasal cannula is an oxygen therapy device that has been commonly used as treatment for patients with hypoxemia. With the adjustable flow of 1-6Lpm, the concentration of the oxygen differs as the breathing pattern of the patient changes.
Study: NCT05298462

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Livzon Rapid Antibody Test for COVID-19
Description: Point-of-care Rapid Antibody Test for COVID-19

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Livzon Rapid Antibody Test for COVID-19
Description: Point-of-care Rapid Antibody Test for COVID-19
Study: NCT02111213

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Advisor
Description: The virtual advisor is named Carmen. She is an animated, computer-generated figure that speaks to participants and gives advice and support for physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Promotora for physical activity
Description: A promotora is a trained, lay health worker. Promotoras will be trained and supervised to provide advice, support and guidance to people to encourage them to be more physically active. They work with people face to face and by telephone to offer support and advice.
Study: NCT02300389

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated IMRT boost radiotherapy
Description: All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with hypofractionated dose of 7.5 Gy in two fractions (II phase) to the total dose of 61 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Fractionated IMRT boost radiotherapy
Description: All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with conventional fractionated dose of 2 Gy in 15 fractions (II phase) to the total dose of 76 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
Study: NCT03906981

Intervention type: OTHER
Intervention: Plaque from each subject will be collected but there will be no intervention
Description: No intervention

Intervention type: OTHER
Intervention: Plaque from each subject will be collected but there will be no intervention
Description: No intervention
Study: NCT02265029

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immediate spa treatment
Description: spa treatment in rheumatology with sedative and antalgique techniques and mobilizing techniques (rehabilitation in pool)
Study: NCT04490941

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ophthalmologist-delivered health education
Description: The educational intervention will be conducted on-site by a qualified, experienced ophthalmologist at an ophthalmic center with goals of building awareness on diabetes symptoms, particularly on diabetic retinopathy, and its risk factors with appropriate management.
Study: NCT02265029

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Late spa treatment
Description: spa treatment in rheumatology with sedative and antalgique techniques and mobilizing techniques (rehabilitation in pool)
Study: NCT02226172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib (PF-04449913)
Description: Oral daily dose of glasdegib (PF-04449913) 100 mg tablet in a continuous regimen of 28-day cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral daily dose of placebo 100 mg tablet in a continuous regimen of 28-day cycles.
Study: NCT03760822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: IV ramucirumab at 8 mg/kg on D1 and D15

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: IV ramucirumab at 8 mg/kg on D1 and D15

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV paclitaxel at 80 mg/m² on D1, D8 and D15
Study: NCT04490941

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care follows standard procedure on diabetes management similar to the routine service provision.
Study: NCT01900691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evolution® Esophageal Stent - Fully Covered
Description: Placement of the Evolution® Esophageal Stent for benign or malignant strictures, fistulas, perforations or leaks with the intention of removal
Study: NCT01026363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferol
Description: Ergocalciferol 50,000 IU capsule, one dose every other day x 5 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: 0.25 mcg tablet once daily for 14 days
Study: NCT03827291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Bilateral administration on each side of 30 ml aliquot containing 10 ml of liposomal bupivacaine (133 mg) and 20 ml of 0.25% bupivacaine (50 mg) in the fascial plane between the QL and psoas major muscles.

Intervention type: OTHER
Group type: OTHER
Intervention: Thoracic epidural analgesia
Description: Historical cohort that received thoracic epidural analgesia
Study: NCT04658745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation
Description: iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere in stroke patients, by using a butterfly shape coil.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intermittent theta burst stimulation
Description: iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere in stroke patients, by using a butterfly shape coil.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Mirror Therapy
Description: Participants will practice the movements with the non-affected hand and try moving the affected arm at the same time to synchronize with the non-affected hand (illusion on the mirror). The movement practice will involve 5 table-top tasks and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes.
Study: NCT01466764

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: An injection of 100 mg Anakinra was administered 1 hour prior to surgery and again 24 hours following surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: An injection of normal saline was administered 1 hour prior to surgery and again 24 hours following surgery.
Study: NCT04879498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monolithic zirconia
Description: To assess the clinical performance and survival of posterior monolithic zirconia fixed partial dentures

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Veneered zirconia
Description: To assess the clinical performance and survival of posterior veneered zirconia fixed partial dentures

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Metal-ceramic
Description: To assess the clinical performance and survival of posterior metal-ceramic fixed partial dentures
Study: NCT04658745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: Participants will practice the movements with the non-affected hand and try moving the affected arm at the same time to synchronize with the non-affected hand (illusion on the mirror). The movement practice will involve 5 table-top tasks and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham intermittent theta burst stimulation
Description: iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere in stroke patients. However, a sham coil will be used, which is not associated with any stimulation effect on the brain.
Study: NCT04065282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 3 cycles before radical surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m2 Q3W, 3 cycles perioperation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m2 bid po D1\~14 Q3W, 3 cycles perioperation
Study: NCT04136535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed，500mg/m²，ivgtt ，d1，q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed，500mg/m²，ivgtt ，d1，q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin，AUC 5.0，ivgtt，d1，q3w，

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin，AUC 5.0，ivgtt，d1，q3w，

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib ，12 mg，po，qd，d1-14，q3w；
Study: NCT01713790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stochastic resonance whole-body vibration
Description: Stochastic resonance whole-body vibration training program over 10 weeks, three times a week with 3 to 6 Hz, Noise 4.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exergame
Description: training program over 10 weeks, three times a week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leg press
Description: training program over 10 weeks, three times a week.
Study: NCT02869269

Intervention type: DEVICE
Intervention: Early stage
Description: patients who classed as clinical stage 1 and 2

Intervention type: DEVICE
Intervention: Late stage
Description: patients who classed as clinical stage 3 and 4
Study: NCT02676986

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Anti-androgen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Anti-androgen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Hormonal therapy (Licenced)
Study: NCT03000673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Specified dose of Enoxaparin on specified days
Study: NCT04658745

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham mirror Therapy
Description: In sham mirror therapy, the mirror will be covered. Participants will practice the movements with the non-affected hand and try moving the affected arm at the same time to move the non-affected hand. The participants cannot receive mirror visual feedback of the paretic upper extremity movement during the therapy. Same as mirror therapy, the movement practice will involve 5 table-top tasks and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes.
Study: NCT01932086

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: White rice diet
Description: All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: White rice diet
Description: All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: White rice diet
Description: All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: White rice diet
Description: All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: White rice diet
Description: All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brown rice diet
Description: All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Brown rice diet
Description: All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brown rice diet
Description: All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min